Altimmune Share Price

Altimmune Share Price

NASDAQ: ALT | Micro Cap | Healthcare
$1.41
-$0.12 (-7.84%) Last updated on 19 Nov, 2026 | 01:24 IST
  • Performance
  • Chart
  • Fundamentals
  • Profit & Loss
  • Balance Sheet
  • Cash Flow
  • Corporate Actions
  • About
  • Price history
  • FAQs

Altimmune Stock Performance

Open
$1.52
Prev. Close
$1.53
Circuit Range
N/A
Day Range
$1.40 - $1.53
Year Range
$1.40 - $6.42
Volume
1,20,494
Average Traded
$1.43

Altimmune Share Price Today

As of 19 November 2026, Altimmune, Inc.'s share price is $1.41. The stock opened at $1.52, compared to its previous close of $1.53. During today's trading session, Altimmune, Inc.'s share price traded between $1.40 and $1.53, with an average price of $1.46. Over the past 52 weeks, the stock has recorded a high of $6.42 and a low of $1.40. In terms of performance, Altimmune, Inc.'s share price has declined by 53.77% over the last six months and is down 73.19% on a year-on-year basis.

Altimmune Share Price Chart

Line chart of the Altimmune price trend over the selected period. The price fell overall, ranging from 1.40 to 1.53, ending at 1.41.
$1.40$1.53
L
Show Current Price
H

Altimmune Stock Fundamentals & Key Indicators

Market Cap
$124.23M
PE Ratio (TTM)
N/A
Dividend Yield
0.00%
EPS (TTM)
$-0.54
Revenue (TTM)
$40.00M
Return On Equity (TTM)
-23.59%
Profit Margin
-220225.00%
Debt to Equity
0.08
Quarterly Earnings Growth YoY
-15.53%

Altimmune Quarterly Profit & Loss

All figures in USD

ParticularsDec 2025Mar 2026Jun 2026Sep 2026
Revenue$0.03$0.00$0.00$0.00
Net Profit-$27.36-$22.86-$22.83-$31.61
Net Profit Margin-91200.00%N/AN/AN/A
Income ChangeN/A16.45%0.13%-38.46%

Altimmune Annual Profit & Loss

All figures in USD

Particulars2022202320242025
Revenue-$0.07$0.43$0.02$0.04
Net Profit-$84.71-$88.45-$95.06-$88.09
Net Profit Margin121014.29%-20569.77%-475300.00%-220225.00%
Income ChangeN/A-4.42%-7.47%7.33%

Altimmune Balance Sheet

All figures in USD Million

Particulars2025202420232022
Non Current Assets1.742.051.0114.12
Current Assets278.19137.25209.63192.81
Total Assets279.93139.31210.64206.93
Non Current Liabilities40.045.334.44.58
Current Liabilities15.010.4712.1417.05
Total Liabilities55.0415.816.5421.64
Shareholders' Equity224.89123.51194.1185.29

Altimmune Cash Flow

Annually

All figures in USD Million

Particulars2025202420232022
Operating-67.54-79.85-75.81-62.67
Investing-132.47-28.3913.73-73.4
Financing206.8410.0486.1156.87

Corporate Actions

Split
Ex-date: 14 Sep 2018

About Altimmune

Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

Altimmune Historical Returns

Share price history by day, with open and close prices and the day's change
MonthOpenCloseChange %
Nov 2026
$2.06
$1.41
-30.71%
Oct 2026
$2.85
$2.04
-28.97%
Sep 2026
$3.08
$2.87
-11.71%
Aug 2026
$2.90
$3.25
+13.86%
Jul 2026
$3.06
$2.85
-5.79%
Jun 2026
$3.03
$3.02
-0.82%
May 2026
$2.57
$3.05
+18.22%
Apr 2026
$3.15
$2.58
-15.96%
Mar 2026
$4.22
$3.07
-28.77%
Feb 2026
$5.55
$4.31
-23.17%
Jan 2026
$3.62
$5.61
+55.62%
Dec 2025
$5.08
$3.60
-31.46%

Altimmune Share Price FAQs